Eurogin is part of the Informa Markets Division of Informa PLC

Informa
Informa

Get your CME & Attendance Certificate!

HPV and Head & Neck Forum

Thursday, March 14 • 9.30 - 18.00
Friday, March 15 • 8.00 - 19.30

Coordinators:
C. J. Brenner (USA) • J. P. Klussmann (Germany)
K. Lang Kuhs (USA) • S. Virani (France)

The EUROGIN HPV and Head & Neck Cancer Forum highlights recent advances and areas of active research in the field of HPV-related head and neck cancers. This year’s Forum features talks on epidemiology and prevention, HPV-OPC screening studies, updates on current management, innovations in surveillance and new discoveries of the molecular landscape of HPV-OPC tumors. The Forum will also feature several debates exploring the utility of screening, treatment de-escalation modalities and risks versus benefits of liquid biopsy testing for surveillance. For scientists and researchers in this field, this is a not to be missed agenda.

Thursday, March 14

9.30 - 11.00

Submitted papers I

Chair: A. Kejner (USA)

Feasibility study OncSaliva – non-invasive specimen for the detection of head and neck cancer via epigenetic biomarkers

L. Wiehle (Germany)

Diagnostic accuracy of HPV16 early antigen serology for HPV-driven oropharyngeal cancer is independent of age and sex

T. Waterboer (Germany)

Quantification of human papillomavirus cell-free DNA from low volume blood plasma samples by digital PCR

F. Rosing (Germany)

Liquid biopsies with circulating plasma HPV–DNA measurements – a clinically applicable surveillance tool for HPV-positive oropharyngeal cancer patients

K. Kronberg Jakobsen (Denmark)

Sex disparities in human papillomavirus-associated oropharyngeal carcinoma de-escalation therapy clinical trials

A. Marrero Gonzalez (USA)

Treatment and prognostic diff erences in oropharyngeal squamous cell carcinoma in two highprevalence HPV areas with distinct healthcare systems: a cross-country comparison between the USA and Denmark

A. L. Fenger Carlander (Denmark)

Preliminary findings from a multi-centre study on human papillomavirus driven head and neck squamous cell carcinomas in a multi-ethnic society

H. Sathasivam (Malaysia)

Prevalence of cystic metastases and HPV in a consecutive cohort of surgically removed branchial cleft cysts

R. Bark (Sweden)

Clinical benefi t following adjuvant therapeutic vaccination with PRGN-2012 is governed by the papilloma microenvironment in patients with RRP

C. Allen (USA)

11.00 - 14.00

Lunch Break

14.00 - 15.30

Epidemiology and prevention of HPV-OPC

Chair: E. Rettig (USA) • H. Robbins (France)

The epidemiology of HPV-positive oropharynx cancer has evolved rapidly over the past several decades, with tremendous geographic variation. Further changes are expected in the near future, as the impact of HPV vaccination takes eff ect. Understanding epidemiologic trends, and the risk factors that drive them, is critical to shaping public health policy and messaging. This session will feature recent trends in oropharyngeal cancer incidence, emerging evidence regarding risk factors for HPV-positive oropharyngeal cancer, and updates on HPV vaccination.

Introduction

E. Rettig (USA) •
H. Robbins (France)

Is the global increase in the incidence of oropharyngeal cancer caused by HPV?

M. Goodman (USA)

Trends in incidence rates of head and neck squamous cell carcinomas overall and by potential relatedness to human papillomavirus, Costa Rica 2006 to 2015

L. Carvajal Roventos (USA)

Oral HPV infection and HIV

N. Osazuwa-Peters (USA)

HPV vaccination for prevention of oral HPV infection

A. Giuliano (USA)

HPV-OPC risk after persistent infection

A. D’Souza (USA)

Discussion and Q&A

E. Rettig (USA) •
H. Robbins (France)

15.30 - 16.00

Coffee Break

16.00 - 18.00

Screening for HPV-OPC

Chair: K. Lang Kuhs (USA) • T. Waterboer (Germany)

Human papillomavirus-driven oropharyngeal squamous cell carcinoma (HPV+OPSCC) is rapidly increasing in many parts of the world. There are no methods for early detection. A major barrier to screening is the inability to identify those at high risk as no precancerous lesion has been identified to date. However, some promising early markers of HPV+OPSCC have recently been discovered. There are several ongoing studies aimed at better understanding whether these biomarkers can be used for screening and early detection of HPV+OPSCC. The purpose of this session is to highlight the most recent findings from these studies and to discuss implications for future trial designs.

Introduction

K. Lang Kuhs (USA) •
T. Waterboer (Germany)

The potential impact of oropharyngeal cancer screening: results from a natural history simulation model

R. Landy (USA)

Modelling risks for OPC and non-OPC cancers among HPV16 E6-seropositives - implications for trial design

H. Robbins (France)

Prediagnostic liquid biopsy

D. Faden (USA)

The Hamburg HPV oropharyngeal cancer screening study (PHORECAST) - an update

T. Waterboer (Germany)

Updates on the VOYAGER and HIV-ENDEAVOR screening studies

K. Lang Kuhs (USA)

PANEL: Pros vs cons of screening for HPV-OPC

T. Waterboer (Germany)
vs A. D’Souza (USA)

Friday, March 15

8.00 - 9.30

Basic science

Chair: C. J. Brenner (USA) • S. Virani (France)

The session on basic science research in HPV-related oropharyngeal cancer provides a comprehensive exploration of cutting-edge techniques in detecting and characterizing Human Papillomavirus (HPV) in oropharyngeal cancer. Experts delve into the molecular intricacies of HPV genomics, emphasizing the role of emerging biomarkers and genetic signatures linked to oropharyngeal malignancies and outcomes. Attendees gain insights into advanced diagnostic tools such as sequencing-based classification and artificial intelligence-based tumor histology classification and discuss their accuracy for predicting cancer progression. Discussions span personalized treatment strategies based on molecular profiles and tumor heterogeneity, shedding light on tailored therapeutic interventions. The session serves as a crucial platform for multidisciplinary collaboration, fostering a deeper understanding of the molecular landscape of HPV-related oropharyngeal cancer and its implications for enhanced diagnostic accuracy and targeted therapeutic advancements.

Introduction

C. J. Brenner (USA) •
S. Virani (France)

The impact of HPV structural alterations and viral load on clinical cancer outcomes

N. Hayes (USA)

Nucleotide diversity in HPV16 viral variants and impact on prognosis

S. Virani (France)

Germline susceptibility loci for HPV-driven oropharynx cancer risk and survival

T. Dudding (UK)

HPV expression heterogeneity as a diagnostic biomarker and potential therapeutic target in oropharynx squamous cell carcinoma

S. Puram (USA)

AI in history

S. Chinn (USA)

Discussion and Q&A

C. J. Brenner (USA) •
S. Virani (France)

9.30 - 10.00

Coffee Break

10.00 - 11.30

Management

Chair: J. P. Klussmann (Germany) • S. Puram (USA)

The management session will cover the latest interdisciplinary study concepts for the treatment of HPV-associated head and neck cancers. Conventional treatment of head and neck cancer with surgery and radiotherapy has significant long-term side effects. Due to the better prognosis of HPV-associated carcinomas, attempts are being made to de-escalate therapy. Therefore, diff erent surgical and radio-oncological strategies are discussed by specialists. The criteria for patient selection is also a crucial factor. Further the optimal therapy in the relapsed or metastasized situation is an important topic. The session will therefore cover important results and considerations for improving the treatment of HPV-associated carcinomas of the head and neck.

Introduction

J. P. Klussmann (Germany) •
S. Puram (USA)

DART2 trial (Mayo)

D. J. Ma (USA)

Questions answered, new questions generated: updates in the management of the neck in the HPV era of OPSCC

A. Kejner (USA)

Treatment of HPV driven recurrent/metastatic head and neck squamous cell carcinoma – primetime for treatment individualization?

K. Klinghammer (Germany)

The trial DAHANCA 34 and the single center TORS results

C. Von Buchwald (Denmark)

The MINimalist Trial (MINT): adjuvant treatment deescalation after surgery for HPV+ oropharyngeal cancer

R. Jackson (USA)

De-escalation of adjuvant radio(chemo)therapy for HPV+ HNSCC - the DELPHI study

A. Linge (Germany)

PANEL: Using TORS to de-escalate, yes or no?

C. Von Buchwald (Denmark) •
D. J. Ma (USA)

11.30 - 13.00

Lunch Break

13.00 - 14.30

Submitted papers II

Chair: N. Hayes (USA)

Exosomal miRNA as possible liquid biomarker for HPV+ head and neck squamous cell carcinoma

M. Oberste (Germany)

Extensive viral studies of HPV16-associated oropharyngeal tumors

I. Doghman (France)

HPV-positive oropharyngeal squamous cell carcinoma–monitoring and early response evaluation using HPVDNA in plasma (MER-HPV)

O. Forslund (Sweden)

NF-κB signaling pathway activity leads to identification of novel molecular biomarkers in HPV-associated head and neck cancer

A. Kothari (USA)

HPV viral load is higher in HPVDNA/p16+ OPSCC as compared to that in HPVDNA+/p16- OPSCC but does not differ significantly between OPSCC subsite

T. Dalianis (Sweden)

Comprehensive mRNA expression profi ling for HPV oncogenes, p16 and cellular biomarkers for determination of HNSCC HPV etiology

L. Liang (Germany)

Line-1 methylation in HPV16-positive oropharyngeal cancer: a potential prognostic marker of poor prognosis

M. Casarotto (Italy)

Tumour infl ammation signature and expression of S100A12 and HLA class I improve survival in HPVnegative hypopharyngeal cancer

R. G. Ursu (Romania)

14.30 - 16.00

Molecular diagnosis and surveillance

Chair: C. J. Brenner (USA) • H. Mirghani (France)

The session on molecular diagnostics and surveillance in HPV-related oropharyngeal cancer features an array of insightful talks followed by a debate on the current utility of HPV ctDNA. An overview of current pathology guidelines sets the stage, discussing the evolving standards for diagnosing and monitoring the disease. Cell-free HPV DNA in both plasma and urine is explored as a non-invasive diagnostic tool, providing a convenient and accessible means of detection. TTMV-HPV DNA for surveillance in the clinic is discussed, shedding light on its potential role in monitoring for disease progression. Furthermore, discussion of a randomized controlled trials that are comparing standard surveillance methods to liquid biopsy-based approaches will add a crucial perspective, offering evidence-based insights into the feasibility and advantages of liquid biopsy in the context of HPV-related oropharyngeal cancer prior to a panel debate on the pros and cons of strategies for implementing ctDNA testing into clinical management.

Introduction

C. J. Brenner (USA) •
H. Mirghani (France)

Cell-free HPV DNA in urine

C. J. Brenner (USA)

TTMV-HPV DNA for surveillance in the clinic

E. Rettig (USA)

Practical considerations for the use of cfHPV16 DNA

J. P. Klussmann (Germany)

Randomized controlled trial of standard vs liquid biopsy-based surveillance

H. Mirghani (France)

PANEL: pros vs cons of liquid biopsy for surveillance

E. Rettig (USA)
vs D. Faden (USA)

16.00 - 16.30

Coffee Break

16.30 - 18.00

Recurrent Respiratory Papillomatosis (RRP)

Chair: S. Best (USA)

Recurrent Respiratory Papillomatosis is a chronic low-risk (HPV 6/11) infection of the upper airway. There are exciting new developments in the prevention, surgical treatment, and non-operative management of this disease that will be reviewed in this panel. Ongoing clinical trials will be highlighted, including novel immunologic therapies that should reduce the operative burden for patients.

Introduction

S. Best (USA)

Epidemiologic trends in RRP

C. Derkay (USA)

Advanced imaging modalities in RRP

J. Jackowska (Poland)

Systemic bevacizumab for treatment of aggressive RRP

A. Klein (USA)

Novel DNA vaccines for RRP: initial results

A. Friedman (USA)

Future of combination therapy and immunotherapy for RRP

C. Allen (USA)

Discussion and Q&A

S. Best (USA)

18.00 - 19.30

Submitted papers III

Chair: T. Dalianis (Sweden)

Evaluation of the attributable fraction and burden of HPV-related oropharyngeal cancers in Greece - the Orpheas study

P. Economopoulou (Greece)

Incidence of oropharyngeal cancer in Brazil, data from the population-based cancer registries during 2000-2020

P. Aristizabal (Brazil)

Australian populations’ attitudes and knowledge of oropharyngeal HPV infection

B. Rumianek (Australia)

Burden of human papillomavirus related to oropharyngeal cancers in European countries: the Broaden study results

L. Alemany (Spain)

Burden of adult-onset recurrent respiratory papillomatosis: a systematic literature review

K. Engelbrecht (UK)

Juvenile onset recurrent respiratory papillomatosis - insights into natural history and risk factors for aggressive disease

A. Sibiya (South Africa)

Prevalence of oral human papillomavirus infection among the general adult population in Hong Kong

R. Xing (China)

Oral human papillomavirus prevalence and risk factors among healthy populations in France, Germany, Spain, the United Kingdom and the United States: results from the PROGRESS (PRevalence of Oral HPV infection, a global aSSessment) study

M. Felsher (USA)

Persistent oral high-risk-HPV-infections and herpes viruses co-infections

S. Rintala (Finland)

Register today

Don't miss out on the the world’s leading international congress on HPV infection and associated cancers. See you in Stockholm, March 13-16, 2024